ReviewNPJ vaccines2022
Toxoplasmosis vaccines: what we have and where to go?
Review in NPJ vaccines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed.
- Live-attenuatedVirulence · 2026Article
- HarnessingAnnals of medicine · 2026Review
- A Live Attenuated AP2X-1-DeficientAnimals : an open access journal from MDPI · 2026Article
- ROP64-DeficientMicroorganisms · 2026Article
- Vaccination with live-attenuated Toxoplasma gondii mutants RHΔtkl1 and PruΔpp2a-c induces protective immunity in sheep.Parasites & vectors · 2026Article
- Multi-epitope mRNA vaccine and protein vaccine protect mice against Toxoplasma gondii.Parasites & vectors · 2026Article
- Next-Generation Vaccines Against Neglected Diseases: New Promises from Genetically Modified Live-Attenuated Parasites and RNA Vaccines.Microorganisms · 2026Review
- Live attenuated RHΔtkl1 and PruΔpp2a-c mutants of Toxoplasma gondii are promising vaccine candidates conferring protection in pigs.Infectious diseases of poverty · 2026Article
- Advances and Translational Challenges inVeterinary sciences · 2026Review
- Integrating design-of-experiments (DOE) optimization and risk assessment towards a safe and simplified electroporation protocol for Toxoplasma gondii.PLoS neglected tropical diseases · 2026Article
- Evaluating how demography and temperature increase might alter the burden of congenital Toxoplasmosis in Africa.PLoS neglected tropical diseases · 2026Article
- Parasitic diseases in heart transplantation: challenges of Toxoplasmosis and Chagas Disease.JHLT open · 2026Review
- ATG5 Plays a Role inTransboundary and emerging diseases · 2026Article
- Nanoparticle-Based Vaccines Against Toxoplasma gondii: Immunological Rationale, Platform Strategies, and Translational Challenges.Transboundary and emerging diseases · 2026Review
- Toxoplasma gondii as a drug for anti-tumor immunotherapy: mechanisms, challenges, and perspectives.Parasite (Paris, France) · 2026Review
- Recombinant ROP8 antigen: diagnostics, immunogenicity, and therapeutic targeting in toxoplasmosis.Frontiers in immunology · 2026Article
- Review
- Changes of cognitive functions and proinflammatory cytokines across the lifespan in latentBrain, behavior, & immunity - health · 2025Article
- Development and Evaluation of Six Novel Recombinant GRA Proteins in Serodiagnosis of Human Toxoplasmosis.Current issues in molecular biology · 2025Article
- Lymphotoxin beta receptorInfection and immunity · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite recent major advances in developing effective vaccines against toxoplasmosis, finding new protective vaccination strategies remains a challenging and elusive goal as it is critical to prevent the disease. Over the past few years, various experimental approaches have shown that developing an effective vaccine against T. gondii is achievable. However, more remains unknown due to its complicated life cycle, difficulties in clinical translation, and lack of a standardized platform. This minireview summarizes the recent advances in the development of T. gondii vaccines and the main obstacles to developing a safe, effective and durable T. gondii vaccine. The successes and failures in developing and testing vaccine candidates for the T. gondii vaccine are also discussed, which may facilitate the future development of T. gondii vaccines.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.